Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant : a registry study from the Chronic Malignancies Working Party of the EBMT. / Forcade, Edouard; Chevret, Sylvie; Finke, Jürgen; Ehninger, Gerhard; Ayuk, Francis; Beelen, Dietrich; Koster, Linda; Ganser, Arnold; Volin, Liisa; Sengeloev, Henrik; Michallet, Mauricette; Tischer, Johanna; Jindra, Pavel; Cascon, Maria Jesús Pascual; Koc, Yener; Arat, Mutlu; Tomaszewska, Agnieszka; Hayden, Patrick; de Witte, Theo; Yakoub-Agha, Ibrahim; Kröger, Nicolaus; Robin, Marie.

I: Bone Marrow Transplantation, Bind 57, Nr. 5, 2022, s. 768-774.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Forcade, E, Chevret, S, Finke, J, Ehninger, G, Ayuk, F, Beelen, D, Koster, L, Ganser, A, Volin, L, Sengeloev, H, Michallet, M, Tischer, J, Jindra, P, Cascon, MJP, Koc, Y, Arat, M, Tomaszewska, A, Hayden, P, de Witte, T, Yakoub-Agha, I, Kröger, N & Robin, M 2022, 'Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT', Bone Marrow Transplantation, bind 57, nr. 5, s. 768-774. https://doi.org/10.1038/s41409-022-01620-x

APA

Forcade, E., Chevret, S., Finke, J., Ehninger, G., Ayuk, F., Beelen, D., Koster, L., Ganser, A., Volin, L., Sengeloev, H., Michallet, M., Tischer, J., Jindra, P., Cascon, M. J. P., Koc, Y., Arat, M., Tomaszewska, A., Hayden, P., de Witte, T., ... Robin, M. (2022). Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation, 57(5), 768-774. https://doi.org/10.1038/s41409-022-01620-x

Vancouver

Forcade E, Chevret S, Finke J, Ehninger G, Ayuk F, Beelen D o.a. Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation. 2022;57(5):768-774. https://doi.org/10.1038/s41409-022-01620-x

Author

Forcade, Edouard ; Chevret, Sylvie ; Finke, Jürgen ; Ehninger, Gerhard ; Ayuk, Francis ; Beelen, Dietrich ; Koster, Linda ; Ganser, Arnold ; Volin, Liisa ; Sengeloev, Henrik ; Michallet, Mauricette ; Tischer, Johanna ; Jindra, Pavel ; Cascon, Maria Jesús Pascual ; Koc, Yener ; Arat, Mutlu ; Tomaszewska, Agnieszka ; Hayden, Patrick ; de Witte, Theo ; Yakoub-Agha, Ibrahim ; Kröger, Nicolaus ; Robin, Marie. / Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant : a registry study from the Chronic Malignancies Working Party of the EBMT. I: Bone Marrow Transplantation. 2022 ; Bind 57, Nr. 5. s. 768-774.

Bibtex

@article{f6c9c128e870435eb9863a55812482dc,
title = "Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT",
abstract = "While in vivo T-cell depletion (TCD) is widely used, its benefit in patients with MDS still remains a matter of debate. This study evaluates the impact of TCD on outcomes, and compares ATG and alemtuzumab, in patients with MDS. 1284 patients from the EBMT registry were included in this study with 470 patients in the no-TCD group and 814 in the TCD group (alemtuzumab N = 168; ATG N = 646). At 6 months, aGVHD III-IV cumulative incidences (CI) for no-TCD, ATG or alemtuzumab groups were 13% vs 14% vs 11% (ns), respectively. At 5 years, CI of chronic GVHD were 64% vs 52% vs 51% (p < 0.00017); and CI of relapse was 23% vs 25% vs 39% (p < 0.0001) for no TCD, ATG and alemtuzumab respectively; OS was 47% vs 46% vs 34% (p = 0.009) respectively; and GRFS was 21% vs 28% and 20% (p = 0.045) respectively. In multivariable analysis, ATG improved GRFS, and alemtuzumab decreased OS. Both ATG and alemtuzumab decreased risk of chronic GVHD, but the increased risk of relapse with alemtuzumab is associated with a poor GRFS and suggest to not use alemtuzumab in the setting of allo-SCT for high risk disease.",
author = "Edouard Forcade and Sylvie Chevret and J{\"u}rgen Finke and Gerhard Ehninger and Francis Ayuk and Dietrich Beelen and Linda Koster and Arnold Ganser and Liisa Volin and Henrik Sengeloev and Mauricette Michallet and Johanna Tischer and Pavel Jindra and Cascon, {Maria Jes{\'u}s Pascual} and Yener Koc and Mutlu Arat and Agnieszka Tomaszewska and Patrick Hayden and {de Witte}, Theo and Ibrahim Yakoub-Agha and Nicolaus Kr{\"o}ger and Marie Robin",
note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2022",
doi = "10.1038/s41409-022-01620-x",
language = "English",
volume = "57",
pages = "768--774",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "nature publishing group",
number = "5",

}

RIS

TY - JOUR

T1 - Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant

T2 - a registry study from the Chronic Malignancies Working Party of the EBMT

AU - Forcade, Edouard

AU - Chevret, Sylvie

AU - Finke, Jürgen

AU - Ehninger, Gerhard

AU - Ayuk, Francis

AU - Beelen, Dietrich

AU - Koster, Linda

AU - Ganser, Arnold

AU - Volin, Liisa

AU - Sengeloev, Henrik

AU - Michallet, Mauricette

AU - Tischer, Johanna

AU - Jindra, Pavel

AU - Cascon, Maria Jesús Pascual

AU - Koc, Yener

AU - Arat, Mutlu

AU - Tomaszewska, Agnieszka

AU - Hayden, Patrick

AU - de Witte, Theo

AU - Yakoub-Agha, Ibrahim

AU - Kröger, Nicolaus

AU - Robin, Marie

N1 - Publisher Copyright: © 2022, The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2022

Y1 - 2022

N2 - While in vivo T-cell depletion (TCD) is widely used, its benefit in patients with MDS still remains a matter of debate. This study evaluates the impact of TCD on outcomes, and compares ATG and alemtuzumab, in patients with MDS. 1284 patients from the EBMT registry were included in this study with 470 patients in the no-TCD group and 814 in the TCD group (alemtuzumab N = 168; ATG N = 646). At 6 months, aGVHD III-IV cumulative incidences (CI) for no-TCD, ATG or alemtuzumab groups were 13% vs 14% vs 11% (ns), respectively. At 5 years, CI of chronic GVHD were 64% vs 52% vs 51% (p < 0.00017); and CI of relapse was 23% vs 25% vs 39% (p < 0.0001) for no TCD, ATG and alemtuzumab respectively; OS was 47% vs 46% vs 34% (p = 0.009) respectively; and GRFS was 21% vs 28% and 20% (p = 0.045) respectively. In multivariable analysis, ATG improved GRFS, and alemtuzumab decreased OS. Both ATG and alemtuzumab decreased risk of chronic GVHD, but the increased risk of relapse with alemtuzumab is associated with a poor GRFS and suggest to not use alemtuzumab in the setting of allo-SCT for high risk disease.

AB - While in vivo T-cell depletion (TCD) is widely used, its benefit in patients with MDS still remains a matter of debate. This study evaluates the impact of TCD on outcomes, and compares ATG and alemtuzumab, in patients with MDS. 1284 patients from the EBMT registry were included in this study with 470 patients in the no-TCD group and 814 in the TCD group (alemtuzumab N = 168; ATG N = 646). At 6 months, aGVHD III-IV cumulative incidences (CI) for no-TCD, ATG or alemtuzumab groups were 13% vs 14% vs 11% (ns), respectively. At 5 years, CI of chronic GVHD were 64% vs 52% vs 51% (p < 0.00017); and CI of relapse was 23% vs 25% vs 39% (p < 0.0001) for no TCD, ATG and alemtuzumab respectively; OS was 47% vs 46% vs 34% (p = 0.009) respectively; and GRFS was 21% vs 28% and 20% (p = 0.045) respectively. In multivariable analysis, ATG improved GRFS, and alemtuzumab decreased OS. Both ATG and alemtuzumab decreased risk of chronic GVHD, but the increased risk of relapse with alemtuzumab is associated with a poor GRFS and suggest to not use alemtuzumab in the setting of allo-SCT for high risk disease.

U2 - 10.1038/s41409-022-01620-x

DO - 10.1038/s41409-022-01620-x

M3 - Journal article

C2 - 35220412

AN - SCOPUS:85125231073

VL - 57

SP - 768

EP - 774

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -

ID: 346594120